Watch How Your Oncotype DX Genomic Prostate Score Can Help You Navigate Your Treatment Options
Oncotype DX is the only test designed specifically for men with clinically low-risk prostate cancer. With it, you get a genomic blueprint to help you build a treatment plan that addresses your cancer AND your quality of life.
Oncotype DX Prostate Cancer Test
Follow an Oncotype DX sample as it makes its way through Genomic Health's lab testing process.
Your Prostate Your Decision
Watch a public service announcement featuring baseball Hall-of-Famer and prostate cancer survivor Joe Torre talk about prostate cancer treatment options and the importance of taking the time to get educated before making a treatment decision. For more information, visit www.yourprostateyourdecision.com.
The Genomic Health Oncotype DX Prostate Cancer Assay
Prostate cancer screenings occur in 23 million men each year, with 240,000 being diagnosed with the affliction. In less severe cases, patients are quick to receive immediate treatment despite the fact that only 3% are likely to have a prostate cancer recurrence. Genomic Health provides a test for prostate cancer patients, called the Oncotype DX Prostate Cancer Test (assay), which will help determine how aggressive the prostate cancer is and aides doctors and patients in forming an individualized course of treatment.